Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Prevail Therapeutics
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05487599CT.gov A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gaucher Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ly3884961 (this asset) | Prevail Therapeutics | P1/2 | CC · 47 |
| Taliglucerase Alfa | Protalix | P4 | A |
| Velaglucerase Alfa | Takeda | P4 | A |
| .Alpha.-D-Glucosyl-N-Acylsphingosine Glucohydrolase | Sanofi | P4 | A |
| Eliglustat | Peking Union Medical College Hospital | P3 | BBB |
| Cerezyme® / Imiglucerase | University Hospital, Clermont-Ferrand | P4 | BBB |
| Isofagomine | Amicus Therapeutics | P2 | BB |
| Sofosbuvir | Mansoura University Children Hospital | P4 | BB |
| Ledipasvir | Mansoura University Children Hospital | P4 | BB |
+20 more in the Gaucher Disease cohort
Other indications for ly3884961
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gaucher Disease Type II | — | P1/2 | CCC · 48 |
| Parkinson Disease | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ly3884961 in Gaucher Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ly3884961-gaucher-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →